Clinical trial
Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory…
NCT00153933 · Dana-Farber Cancer Institute, Other · Completed
Key facts
| NCT number | NCT00153933 |
|---|---|
| Title | Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma |
| Official title | An Open-Label Phase I Study of the Safety and Efficacy of Bortezomib in Combination With CC-5013 in the Treatment of Subjects With Relapsed and Relapsed/Refractory Multiple Myeloma |
| Lead sponsor | Dana-Farber Cancer Institute, Other |
| Collaborators | Beth Israel Deaconess Medical Center Brigham and Women's Hospital H. Lee Moffitt Cancer Center and Research Institute |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma |
| Intervention type | Drug |
| Interventions | Bortezomib, CC-5013 |
| Enrollment | 58 |
| Start date | Aug 1, 2004 |
| Primary completion | Jul 1, 2014 |
| Completion | Jul 1, 2014 |
| First posted | Sep 12, 2005 |
| Last update posted | Jan 25, 2016 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: